Ebglyss by Eli Lilly Shows Strong Results in Pediatric Dermatitis

Eli Lilly and Company has reported positive topline results for Ebglyss (lebrikizumab-lbkz) from the Phase 3 ADorable-1 trial, marking a key step forward in treating children with moderate-to-severe atopic dermatitis.

The Ebglyss study met its primary and secondary endpoints at Week 16, showing clear improvements in disease severity, skin clearance, and itch relief.

Atopic dermatitis affects about 9.6 million children in the U.S., with nearly one-third experiencing moderate-to-severe disease. In the ADorable-1 trial, 363 pediatric patients, including infants as young as six months, received either placebo or weight-based doses of Ebglyss alongside topical corticosteroids. Patients who improved could reduce or stop steroid use. Results showed strong responses across key measures, including EASI-75, EASI-90, and significant itch reduction.

Also Read: Advancing Interventional Radiology in India Through Collaboration

Ebglyss works by targeting interleukin-13 (IL-13), a key driver of inflammation in eczema. By blocking IL-13 signaling, the treatment helps restore the skin barrier and reduce symptoms like itching and thickened skin.

"Children with moderate-to-severe atopic dermatitis often endure relentless skin flares, itch and discomfort that can disrupt play, school and daily life for patients and caregivers," said Adrienne Brown, executive vice president and president, Lilly Immunology."

Safety findings were consistent with earlier studies, with no new concerns reported. The most common side effects included upper respiratory infections and nasopharyngitis.

Amy Paller added, "Despite the high prevalence of moderate-to-severe atopic dermatitis in infants and young children, they have fewer approved treatment options than adults and adolescents. The topline results from ADorable-1 offer hope for these young patients, delivering near-complete skin clearance and significant itch relief with a highly selective medicine that targets the underlying inflammation that drives this chronic disease."